http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2218779-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b97c948c84a801e5cad5634c3a536c77 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y402-02004 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-88 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-88 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04 |
| filingDate | 2003-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb5c414ce6cedc0c464475840338bc0b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc184f88d82ff98d033ce4e147e32677 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b025a75662e85a65aae188583f58e58c |
| publicationDate | 2010-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2218779-A1 |
| titleOfInvention | Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof |
| abstract | The invention relates to the discovery of a novel Chondroitinase Glycoproteins (CHASEGP's), methods of manufacture, and potential uses in conditions where removal of chondroitin sulfates may be of therapeutic benefit. Chondroitinase Glycoproteins require both a substantial portion of the catalytic domain of the CHASEGP polypeptide and asparagine-linked glycosylation for optimal chondroitinase activity. The invention also includes carboxy-terminal deletion variants of CHASEGP that result in secreted variants of the protein to facilitate manufacture of a recombinant CHASEGP. Further described are suitable formulations of a substantially purified recombinant CHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.; CHASEGP is useful for the degradation of glycosaminoglycans and chondroitin sulfate proteoglycans under clinical conditions where their removal is of therapeutic value. |
| priorityDate | 2002-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 2641.